Literature DB >> 8992939

Randomized trial of aspirin versus aspirin and heparin in pregnant women with the antiphospholipid syndrome.

H Cohen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8992939

Source DB:  PubMed          Journal:  Ann Med Interne (Paris)        ISSN: 0003-410X


× No keyword cloud information.
  6 in total

1.  Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Eva N Hamulyák; Luuk Jj Scheres; Mauritia C Marijnen; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2020-05-02

Review 2.  Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.

Authors:  M Empson; M Lassere; J Craig; J Scott
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 3.  Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.

Authors:  Rebecca Tooher; Simon Gates; Therese Dowswell; Lucy-Jane Davis
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

4.  Care prior to and during subsequent pregnancies following stillbirth for improving outcomes.

Authors:  Aleena M Wojcieszek; Emily Shepherd; Philippa Middleton; Zohra S Lassi; Trish Wilson; Margaret M Murphy; Alexander Ep Heazell; David A Ellwood; Robert M Silver; Vicki Flenady
Journal:  Cochrane Database Syst Rev       Date:  2018-12-17

5.  Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.

Authors:  Philippa Middleton; Emily Shepherd; Judith C Gomersall
Journal:  Cochrane Database Syst Rev       Date:  2021-03-29

Review 6.  Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies.

Authors:  Malgorzata M Bala; Elżbieta Paszek; Wiktoria Lesniak; Dorota Wloch-Kopec; Katarzyna Jasinska; Anetta Undas
Journal:  Cochrane Database Syst Rev       Date:  2018-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.